R&D spending: $74,452,000
Percentage of revenues: 16.1%
2018 overall revenue ranking: 82Insulet (Billerica, Mass.) is the maker of the Omnipod insulin management device, which it markets as a wearable, tubeless and seamless way to deliver insulin to those who have diabetes.
The Omnipod delivery system is customizable for a number of injectable drugs. It is an automated drug delivery platform that offers improved adherence, outcomes and differentiation throughout a drug’s lifecycle, according to the company.
Omnipod features an adhesive backing for extended wear and programmable technology that allows users to customize for any delivery regimen. It is also waterproof to allow for uninterrupted “life-proof adherence,” Insulet says on its website. Omnipod also has a soft delivery cannula for a comfortable and “virtually painless” experience.
The device has shown better adherence with its wearable design for continuous delivery and automated dosing within therapeutic windows. It also has shown improved outcomes by reducing the potential for missed or inaccurate dosing with its customizable delivery of complex dosing regimens.
You may also like: